WEKO3
アイテム
{"_buckets": {"deposit": "a77f17b5-7b09-435f-a397-81598ebb2407"}, "_deposit": {"created_by": 6, "id": "26357", "owners": [6], "pid": {"revision_id": 0, "type": "depid", "value": "26357"}, "status": "published"}, "_oai": {"id": "oai:nagasaki-u.repo.nii.ac.jp:00026357", "sets": ["9"]}, "author_link": ["117455", "117456", "117461", "117465", "117464", "117459", "117453", "117450", "117463", "117457", "117458", "117466", "117452", "117460", "117454", "117462", "117451"], "item_2_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2021-02-11", "bibliographicIssueDateType": "Issued"}, "bibliographicPageStart": "100739", "bibliographicVolumeNumber": "21", "bibliographic_titles": [{"bibliographic_title": "Contemporary Clinical Trials Communications"}]}]}, "item_2_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Survival of patients with breast cancer can be prolonged by treatment with drugs, particularly new molecular-targeted drugs. However, these agents can be expensive and such treatments can be “an economic burden.” In this ongoing trial, we aim to assess the usefulness of ChemoCalc, a software package for calculating drug costs, to help patients understand the financial outlays. In this multicenter, randomized controlled phase 2 trial, 106 patients with advanced breast cancer will be assigned to either the “ChemoCalc” or “Usual Explanation” group. Treatment using ChemoCalc will be discussed with patients in the ChemoCalc group, whereas standard treatments, without using ChemoCalc, will be discussed with patients in the Usual Explanation group. Subsequently, the participants will decide the treatment and complete a five-grade evaluation questionnaire; those in the Usual Explanation group will receive information about ChemoCalc. Investigators will report if patients subsequently decide to change treatments. The primary endpoint will be the scores of two key questions compared between the groups: “Did you understand the cost of treatment in today\u0027s discussion?” and “Do you think the cost of treatment is important in choosing a treatment?“. The secondary endpoints will be to compare discrepancies between treatments recommended by physicians and those selected by patients, the time required for discussion, other questionnaire factors, and the relationship between Comprehensive Score for Financial Toxicity tool and treatment selection. This will be the first randomized controlled trial to assess the efficacy of software to help patients understand drug cost estimates and whether it subsequently affects treatment choice. This study will be conducted according to the CONSORT statement. All participants will sign a written consent form. The study protocol was reviewed and approved by the Clinical Research Review Board of Nagasaki University (19070801). The protocol (version 1) was designed and will be conducted in accordance with the Declaration of Helsinki (1964) and the Ethical Guidelines for Medical and Health Research Involving Human Subjects (2017). The findings will be disseminated through scientific and professional conferences, and in peer-reviewed journals.", "subitem_description_type": "Abstract"}]}, "item_2_description_63": {"attribute_name": "引用", "attribute_value_mlt": [{"subitem_description": "Contemporary Clinical Trials Communications, 21, art.no.100739; 2021", "subitem_description_type": "Other"}]}, "item_2_publisher_33": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Elsevier Inc."}]}, "item_2_relation_12": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isIdenticalTo", "subitem_relation_type_id": {"subitem_relation_type_id_text": "10.1016/j.conctc.2021.100739", "subitem_relation_type_select": "DOI"}}]}, "item_2_rights_13": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "©2021 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/) "}]}, "item_2_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "24518654", "subitem_source_identifier_type": "ISSN"}]}, "item_2_version_type_16": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Kuba, Sayaka"}], "nameIdentifiers": [{"nameIdentifier": "117450", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Moriuchi, Hiroki"}], "nameIdentifiers": [{"nameIdentifier": "117451", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yamanouchi, Kosho"}], "nameIdentifiers": [{"nameIdentifier": "117452", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Shibata, Kenichiro"}], "nameIdentifiers": [{"nameIdentifier": "117453", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yano, Hiroshi"}], "nameIdentifiers": [{"nameIdentifier": "117454", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Oikawa, Masahiro"}], "nameIdentifiers": [{"nameIdentifier": "117455", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Maeda, Shigeto"}], "nameIdentifiers": [{"nameIdentifier": "117456", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Meng, Xiangyue"}], "nameIdentifiers": [{"nameIdentifier": "117457", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Morita, Michi"}], "nameIdentifiers": [{"nameIdentifier": "117458", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hatachi, Toshiko"}], "nameIdentifiers": [{"nameIdentifier": "117459", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Otsubo, Ryota"}], "nameIdentifiers": [{"nameIdentifier": "117460", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Matsumoto, Megumi"}], "nameIdentifiers": [{"nameIdentifier": "117461", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Miyamoto, Junya"}], "nameIdentifiers": [{"nameIdentifier": "117462", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kanetaka, Kengo"}], "nameIdentifiers": [{"nameIdentifier": "117463", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Taniguchi, Hideki"}], "nameIdentifiers": [{"nameIdentifier": "117464", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nagayasu, Takeshi"}], "nameIdentifiers": [{"nameIdentifier": "117465", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Eguchi, Susumu"}], "nameIdentifiers": [{"nameIdentifier": "117466", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2021-03-19"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "CCTC21_100739.pdf", "filesize": [{"value": "3.7 MB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 3700000.0, "url": {"label": "CCTC21_100739.pdf ", "url": "https://nagasaki-u.repo.nii.ac.jp/record/26357/files/CCTC21_100739.pdf"}, "version_id": "72d48ae8-0e98-4fca-b5af-9fa072199a99"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "Breast cancer", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Clinical trials communication", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Oncology", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Protocol for studying the efficiency of ChemoCalc software in helping patients to understand drug treatment costs for breast cance", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Protocol for studying the efficiency of ChemoCalc software in helping patients to understand drug treatment costs for breast cance"}]}, "item_type_id": "2", "owner": "6", "path": ["9"], "permalink_uri": "http://hdl.handle.net/10069/00040554", "pubdate": {"attribute_name": "公開日", "attribute_value": "2021-03-19"}, "publish_date": "2021-03-19", "publish_status": "0", "recid": "26357", "relation": {}, "relation_version_is_last": true, "title": ["Protocol for studying the efficiency of ChemoCalc software in helping patients to understand drug treatment costs for breast cance"], "weko_shared_id": -1}
Protocol for studying the efficiency of ChemoCalc software in helping patients to understand drug treatment costs for breast cance
http://hdl.handle.net/10069/00040554
http://hdl.handle.net/10069/00040554f54560c3-99e8-4091-b2a2-04c4326685f1
名前 / ファイル | ライセンス | アクション |
---|---|---|
CCTC21_100739.pdf (3.7 MB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2021-03-19 | |||||
タイトル | ||||||
タイトル | Protocol for studying the efficiency of ChemoCalc software in helping patients to understand drug treatment costs for breast cance | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Breast cancer | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Clinical trials communication | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Oncology | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
Kuba, Sayaka
× Kuba, Sayaka× Moriuchi, Hiroki× Yamanouchi, Kosho× Shibata, Kenichiro× Yano, Hiroshi× Oikawa, Masahiro× Maeda, Shigeto× Meng, Xiangyue× Morita, Michi× Hatachi, Toshiko× Otsubo, Ryota× Matsumoto, Megumi× Miyamoto, Junya× Kanetaka, Kengo× Taniguchi, Hideki× Nagayasu, Takeshi× Eguchi, Susumu |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Survival of patients with breast cancer can be prolonged by treatment with drugs, particularly new molecular-targeted drugs. However, these agents can be expensive and such treatments can be “an economic burden.” In this ongoing trial, we aim to assess the usefulness of ChemoCalc, a software package for calculating drug costs, to help patients understand the financial outlays. In this multicenter, randomized controlled phase 2 trial, 106 patients with advanced breast cancer will be assigned to either the “ChemoCalc” or “Usual Explanation” group. Treatment using ChemoCalc will be discussed with patients in the ChemoCalc group, whereas standard treatments, without using ChemoCalc, will be discussed with patients in the Usual Explanation group. Subsequently, the participants will decide the treatment and complete a five-grade evaluation questionnaire; those in the Usual Explanation group will receive information about ChemoCalc. Investigators will report if patients subsequently decide to change treatments. The primary endpoint will be the scores of two key questions compared between the groups: “Did you understand the cost of treatment in today's discussion?” and “Do you think the cost of treatment is important in choosing a treatment?“. The secondary endpoints will be to compare discrepancies between treatments recommended by physicians and those selected by patients, the time required for discussion, other questionnaire factors, and the relationship between Comprehensive Score for Financial Toxicity tool and treatment selection. This will be the first randomized controlled trial to assess the efficacy of software to help patients understand drug cost estimates and whether it subsequently affects treatment choice. This study will be conducted according to the CONSORT statement. All participants will sign a written consent form. The study protocol was reviewed and approved by the Clinical Research Review Board of Nagasaki University (19070801). The protocol (version 1) was designed and will be conducted in accordance with the Declaration of Helsinki (1964) and the Ethical Guidelines for Medical and Health Research Involving Human Subjects (2017). The findings will be disseminated through scientific and professional conferences, and in peer-reviewed journals. | |||||
書誌情報 |
Contemporary Clinical Trials Communications 巻 21, p. 100739, 発行日 2021-02-11 |
|||||
出版者 | ||||||
出版者 | Elsevier Inc. | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 24518654 | |||||
DOI | ||||||
関連タイプ | isIdenticalTo | |||||
識別子タイプ | DOI | |||||
関連識別子 | 10.1016/j.conctc.2021.100739 | |||||
権利 | ||||||
権利情報 | ©2021 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/) | |||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
引用 | ||||||
内容記述タイプ | Other | |||||
内容記述 | Contemporary Clinical Trials Communications, 21, art.no.100739; 2021 |